NEURONETICS, INC.

Analyst Reco. Neuronetics, Inc.

Equities

STIM

US64131A1051

Real-time Estimate Cboe BZX Other stock markets 10:25:52 2024-04-25 am EDT			5-day change	1st Jan Change
3.645 ^USD	-2.80%		-3.66%	+27.24%

Apr. 10	Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation	CI
Mar. 28	Neuronetics, Inc. Announces John K. Bakewell, Joseph H. Capper and Dr. Wilfred E. Jaeger Not Stand for Reelection to the Board	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Canaccord Genuity Adjusts Price Target on Neuronetics to $7 From $9, Maintains Buy Rating	23-03-08	MT
Piper Sandler Adjusts Neuronetics' Price Target to $9 From $10, Reiterates Overweight Rating	22-01-03	MT
NEURONETICS : JMP Securities Adjusts Price Target on Neuronetics to $12 From $18, Maintains Market Outperform Rating	21-10-14	MT
NEURONETICS : William Blair Downgrades Neuronetics to Market Perform From Outperform	21-10-13	MT
NEURONETICS : BTIG Downgrades Neuronetics to Neutral from Buy	21-10-13	MT
NEURONETICS : William Blair Upgrades Neuronetics to Outperform From Market Perform	21-01-22	MT
NEURONETICS : Piper Sandler Adjusts Neuronetics' Price Target to $27 from $20, Keeps Overweight Rating	21-01-21	MT
NEURONETICS : BTIG Research Adjusts Neuronetics PT to $21 From $14, Maintains Buy Rating	21-01-21	MT
NEURONETICS : BTIG Research Adjusts Neuronetics PT to $14 From $10, Maintains Buy Rating	20-12-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer